MRK
MRK clinical trials: Merck & Co., Inc.
Every trial on ClinicalTrials.gov where Merck & Co., Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 4,810
- Trials linked
- 2,432
- As lead sponsor
- 2,378
- As collaborator
- 16
- Primary completions as lead sponsor, next 90 days
MRK on the catalyst calendar · MRK registry changes
- Primary completion Jul 31, 2027Sponsor estimatePhase 2NCT07225959A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07)Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Healthy ParticipantsActive, not recruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 10, 2027Sponsor estimatePhase 2NCT07862595A Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery (MK-6916-007)Merck Sharp & Dohme LLC · Pain ManagementRecruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 3, 2026ActualPhase 3NCT07216482A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)Merck Sharp & Dohme LLC · HyperlipidemiaCompletedMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 24, 2029Sponsor estimatePhase 2NCT07862569DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kgMerck Sharp & Dohme LLC · HIV-1Not yet recruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 19, 2032Sponsor estimatePhase 3NCT07776691A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian...Merck Sharp & Dohme LLC · Ovarian CancerRecruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 31, 2031Sponsor estimatePhase 3NCT07743164A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed...Merck Sharp & Dohme LLC · Ovarian CancerRecruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 27, 2029Sponsor estimatePhase 3NCT07419295A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)Merck Sharp & Dohme LLC · Bladder CancerRecruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 25, 2033Sponsor estimatePhase 3NCT07318558A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)Merck Sharp & Dohme LLC · Ovarian NeoplasmsRecruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT07300085A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Healthy ParticipantsRecruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 29, 2031Sponsor estimatePhase 3NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of...Merck Sharp & Dohme LLC · Cervical CancerRecruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 23, 2033Sponsor estimatePhase 3NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Merck Sharp & Dohme LLC · Breast NeoplasmsRecruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 24, 2032Sponsor estimatePhase 3NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment...Merck Sharp & Dohme LLC · Endometrial CancerRecruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 18, 2030Sponsor estimatePhase 3NCT06841354A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants...Merck Sharp & Dohme LLC · Triple Negative Breast NeoplasmsRecruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 27, 2029Sponsor estimatePhase 3NCT06824467A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in...Merck Sharp & Dohme LLC · Ovarian CancerRecruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 26, 2031Sponsor estimatePhase 3NCT06667700A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk...Merck Sharp & Dohme LLC · Coronavirus Disease (COVID-19)RecruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 12, 2029Sponsor estimatePhase 3NCT06422143Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer...Merck Sharp & Dohme LLC · Non-small Cell Lung CancerRecruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 16, 2030Sponsor estimatePhase 3NCT06393374Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Merck Sharp & Dohme LLC · Triple-Negative Breast CancerRecruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 7, 2032Sponsor estimatePhase 3NCT06136559A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic...Merck Sharp & Dohme LLC · Chronic Lymphocytic LeukemiaRecruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 1, 2032Sponsor estimatePhase 3NCT05947851A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic...Merck Sharp & Dohme LLC · Leukemia, Lymphocytic, Chronic, B-CellRecruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 4, 2029Sponsor estimatePhase 2NCT04728893Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)Merck Sharp & Dohme LLC · Hematologic MalignanciesRecruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 22, 2034Sponsor estimatePhase 3NCT07513376A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in...Merck Sharp & Dohme LLC · Non-small Cell Lung CancerRecruitingMRKLeadMRNACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 16, 2033Sponsor estimatePhase 3NCT06623422A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer...Merck Sharp & Dohme LLC · Carcinoma, Non-Small-Cell LungRecruitingMRKLeadMRNACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 25, 2030Sponsor estimatePhase 3NCT06077760A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell...Merck Sharp & Dohme LLC · Non-small Cell Lung CancerActive, not recruitingMRKLeadMRNACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 19, 2027Sponsor estimatePhase 2NCT07895524A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)Merck Sharp & Dohme LLC · Rheumatoid ArthritisNot yet recruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 29, 2029Sponsor estimatePhase 3NCT07874815Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History...Merck Sharp & Dohme LLC · Pulmonary Disease, Chronic ObstructiveRecruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 4,785 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner